New Brunswick Scientific to Introduce Five Innovative New Products at the American Society for Microbiology (ASM) General Meetin
27 Mai 2005 - 5:09PM
PR Newswire (US)
New Brunswick Scientific to Introduce Five Innovative New Products
at the American Society for Microbiology (ASM) General Meeting
EDISON, N.J., May 27 /PRNewswire-FirstCall/ -- New Brunswick
Scientific Co., Inc. (NBS) (NASDAQ:NBSC), yesterday announced that
it will be introducing five innovative new products at the American
Society for Microbiology (ASM) General Meeting, which opens on June
6th in Atlanta, GA. The announcement by James Orcutt, NBS President
and COO, was made during an open question and answer forum at the
Company's annual shareholders' meeting. The products were
identified as two new biological shakers, Innova(R) 40, a benchtop
incubated and refrigerated system; and Innova 43, a larger-scale
floor model. Innova shakers are the workhorses of the industry,
known for precision control of operating parameters and
exceptionally long life. With this latest complement to its shaker
family, the Company now offers over 30 shaker models -- the largest
selection offered by any manufacturer -- providing life scientists
with a range of options to suit virtually any culture requirement.
A new slim upright, 360 liter capacity, ultra-low temperature
freezer, Innova U360, will also be introduced. This latest freezer
in the Innova family utilizes vacuum-insulation panel technology in
place of traditional insulating foam. Vacuum-insulation panels
reduce wall thickness, thereby maintaining a small footprint while
increasing interior storage capacity. With the addition of the
Innova U360, the Company now offers ten freezer models, including a
unique personal-sized unit for on- or under-bench use. Mr. Orcutt
also announced plans to introduce a new 500 mL disposable cell
culture system. FibraStage(TM), the first truly disposable product
in NBS' product range, offers the simplicity of operation and
convenience of disposable technology, while providing higher yields
than typically achieved using traditional culture systems, such as
spinners, T-flasks and roller bottles. He went on to explain that
the Company's proprietary FibraCel(R) disks, which are at the heart
of the FibraStage system, are currently being used to produce the
world's first licensed gene therapy drug. Rounding out the new
product introductions is the NucleoCounter YC-100, a device for
more accurately and automatically counting yeast cells. The YC-100
serves as a counterpoint to the original NucleoCounter, which
automates the tedious task of counting mammalian cells. Mr. Orcutt
commented that "accelerated and targeted new product development is
among several strategic initiatives upon which NBS is focused. With
the introduction of these products at ASM, the results of this
sustained effort are beginning to show." To be added to New
Brunswick Scientific's e-mail distribution list, please click on
the link below:
http://www.clearperspectivegroup.com/clearsite/nbsc/emailoptin.html
About New Brunswick Scientific New Brunswick Scientific Co., Inc.,
is a leading global provider of a comprehensive line of research
equipment and scientific instrumentation for use in the life
science industry. The Company's products are used in the creation,
maintenance and control of physical and biochemical environments
required for the growth, detection and storage of microorganisms
for medical, biological and chemical applications, as well as
environmental research and commercial product development. NBS is a
forerunner in the research and development of pioneering equipment
to meet the challenges of new areas of advancement in life science.
Established in 1946, New Brunswick Scientific is headquartered in
Edison, New Jersey, with sales and distribution facilities
strategically located in the United States, Europe and Asia. For
more information, please visit http://www.nbsc.com/ . This document
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by words such as "expects,"
"anticipates," "intends," "plans," "believes," "seeks,"
"estimates," "will" or words of similar meaning and include, but
are not limited to, statements about the expected future business
and financial performance of the Company. The forward-looking
statements involve a number of risks and uncertainties, including
but not limited to, changes in economic conditions, demand for the
Company's products, pricing pressures, intense competition in the
industries in which the Company operates, the need for the Company
to keep pace with technological developments and respond in a
timely manner to changes in customer needs, the Company's
dependence on third-party suppliers, the effect on foreign sales of
currency fluctuations, acceptance of new products, the labor
relations of the Company and its customers and other factors
identified in the Company's Securities and Exchange Commission
filings. Forward-looking statements are based on management's
current expectations and assumptions, which are inherently subject
to uncertainties, risks and changes in circumstances that are
difficult to predict. Actual outcomes and results may differ
materially from these expectations and assumptions due to changes
in global political, economic, business, competitive, market,
regulatory and other factors. The Company undertakes no obligation
to publicly update or review any forward-looking information,
whether as a result of new information, future developments or
otherwise. DATASOURCE: New Brunswick Scientific Co., Inc. CONTACT:
Samuel Eichenbaum, Vice President, Finance and Treasurer, New
Brunswick Scientific Co., Inc., +1-732-650-2500, ; Matthew J.
Dennis, CFA, NBS Investor Relations, Clear Perspective Group, LLC,
+1-440-353-0552, , for New Brunswick Scientific Co., Inc. Web site:
http://www.nbsc.com/
Copyright
New Brunswick Scientific (NASDAQ:NBSC)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
New Brunswick Scientific (NASDAQ:NBSC)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024